Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically? Results from the Changsha study

Asian Journal of Psychiatry

Volumn 5, Issue 1, 2012, Pages 73-82

  Stone, William S ^a   Hsi, Xiaolu ^a,d   Giuliano, Anthony J ^a   Tan, Liwen ^b   Zhu, Shaochun ^a   Li, Lingjiang ^b   Seidman, Larry J ^a   Tsuang, Ming T ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Negative symptoms; Neurocognitive; Risperidone; Schizophrenia; Schizotaxia

Indexed keywords

PLACEBO; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG INDUCED HEADACHE; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MALE; NEUROLOGIC EXAMINATION; PATIENT ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SELF REPORT; SIDE EFFECT; SOCIAL DISABILITY; SOCIAL STATUS; TREATMENT DURATION; WEIGHT GAIN; XEROSTOMIA; ADOLESCENT; CHINA; CLUSTER ANALYSIS; COGNITIVE DYSFUNCTION; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY; SCHIZOTYPAL PERSONALITY DISORDER; SOCIAL ADAPTATION; SOCIAL BEHAVIOR; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHINA; CLUSTER ANALYSIS; COGNITIVE DYSFUNCTION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SCHIZOTYPAL PERSONALITY DISORDER; SOCIAL ADJUSTMENT; SOCIAL BEHAVIOR; YOUNG ADULT;

EID: 84862776539     PISSN: 18762018     EISSN: 18762026     Source Type: Journal    
DOI: 10.1016/j.ajp.2011.12.001     Document Type: Article

References (38)

1. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 1994, American Psychiatric Association, Washington, DC. 4th ed.
2. Andreasen N.C. The Scale for the Assessment of Negative Symptoms (SANS) 1983, The University of Iowa, Iowa City, Iowa.
3. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Earlbaum, Hillsdale, NJ. 2nd ed.
4. Cuesta M.J., Peralta V., Zarzuela A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr. Res. 2001, 163:17-28.
5. Dazzan P., Kravariti E., Fearon P., Murray R.M. Is the development of schizophrenia predictable?. Early Clinical Intervention and Prevention in Schizophrenia 2004, 225-252. Humana Press, Totowa, NJ. W.S. Stone, S.V. Faraone, M.T. Tsuang (Eds.).
6. Derogatis L.R. Symptom Checklist-90-R (SCL-90-R) 1993, Computer Systems, Inc., Minneapolis, MN.
7. Eack S.M., Greenwald D.P., Hogarty S.S., Cooley S.J., DiBarry A.L., Montrose D.M., Keshavan M.S. Cognitive enhancement therapy for early-course schizophrenia: effects of a 2-year randomized controlled trial. Psychiatry Serv. 2009, 60:1468-1476.
8. Eack S.M., Greenwald D.P., Hogarty S.S., Keshavan M.S. One-year durability of the effects of cognitive enhancement therapy on functional outcome in early schizophrenia. Schizophr. Res. 2010, 120:210-216.
9. Faraone S.V., Green A.I., Seidman L.J., Tsuang M.T. Schizotaxia: clinical implications and new directions for research. Schizophr. Bull. 2001, 27:1-18.
10. Glatt S.J., Stone W.S., Faraone S.V., Seidman L.J., Tsuang M.T. Psychopathology, personality traits, and social development of adolescent and young adult first-degree relatives of schizophrenia patients. Br. J. Psychiatry 2006, 189:337-345.
11. Goldberg T.E., Gomar J.J. Targeting cognition in schizophrenia research: from etiology to treatment. Am. J. Psychiatry 2009, 166:631-634.
12. Goldberg T.E., David A., Gold J.M. Neurocognitive impairments in schizophrenia: their character and role in symptom formation. Schizophrenia 2011, 142-162. Wiley-Blackwell, Oxford. 3rd ed. D.R. Weinberger, P.J. Harrison (Eds.).
13. Goto N., Yohimura R., Kakeda S., Moriya J., Hayashi K., Ikenouchi-Sugita A., Umene-Nakano W., Hori H., Ueda N., Korogi Y., Nakamura J. Associations between plasma levels of 3-methoxy-4-hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early-stage schizophrenia. Hum. Psychopharmcaol. 2009, 24:639-645.
14. Hair J.F., Black W.C. Cluster analysis. Reading and Understanding More Multivariate Statistics 2000, 147-205. American Psychological Association, Washington, DC. L.G. Grimm, P.R. Yarnold (Eds.).
15. Houthoofd S.A., Morrens M., Sabbe B.G. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin. Therapy 2008, 30:1565-1589.
16. Kaufman L., Rousseau P. Finding Groups in Data 1990, Wiley, New York.
17. Keefe R.S.E., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., Meltzer H.Y., Green M.F., Capuano G., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Davis C.E., Hsiao J.K., Lieberman J.A., Investigators C., Group N.W. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch. Gen. Psychiatry 2007, 64:633-647.
18. Keefe R.S.E., Sweeney J.A., Gu H., Hamer R.M., Perkins D.O., McEvoy J.P., Lieberman J.A. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am. J. Psychiatry 2007, 164:1061-1071.
19. Kendler K.S., Lieberman J.A., Walsh D. The structured interview for schizotypy (SIS): a preliminary report. Schizophr. Bull. 1989, 15:559-571.
20. Keshavan M.S., Montrose D.M., Rajarethinam R., Diwadkar V., Prasad K., Sweeney J.A. Psychopathology among offspring of parents with schizophrenia: relationship to premorbid impairments. Schizophr. Res. 2008, 103:114-120.
21. Keshavan M.S., Kulkarni S., Bhojraj T., Francis A., Diwadkar V., Montrose D.M., Seidman L.J., Sweeney J. Premorbid cognitive deficits in young relatives of schizophrenia patients. Frontiers Hum. Neurosci. 2010, 3:62.
22. Koenigsberg H.W., Reynolds D., Goodman M., New A.S., Mitropoulou V., Trestman R.L., Silverman J., Siever L.J. Risperidone in the treatment of schizotypal personality disorder. J. Clin. Psychiatry 2003, 64:628-634.
23. Kremen W.S., Seidman L.J., Faraone S.V., Toomey R., Tsuang M.T. Heterogeneity of schizophrenia: a study of individual neuropsychological profiles. Schizophr. Res. 2004, 71:307-321.
24. Meehl P.E. Schizotaxia, schizotypy, schizophrenia. Am. Psychol. 1962, 17:827-838.
25. Nurnberger J.I., Blehar M.C., Kaufmann C.A., York-Cooler C., Simpson S.G., Harkavy-Friedman J., Severe J.B., Malaspina D., Reich T., Miller M., Bowman E.S., DePaulo J.R., Cloninger C.R., Robinson G., Moldin S., Gershon E.S., Maxwell E., Guroff J.J., Kirch D., Wynne D., Berg K., Tsuang M.T., Faraone S.V., Pepple J.R., Ritz A.L. Diagnostic interview for genetic studies. Rationale, unique features, and training. Arch. Gen. Psychiatry 1994, 51:849-859.
26. Penn D.L., Keefe R.S.E., Davis S.M., Meyer P.S., Perkins D.O., Losardo D., Lieberman J.A. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr. Res. 2009, 115:17-23.
27. Rybakowski J.K., Drozdz W., Borkowska A. Long-term administration of low-dose risperidone in schizotaxia subjects. Hum. Psychopharmacol. 2007, 22:407-412.
28. SPSS SPSS for Windows, Release 16 2008, SPSS Inc., Chicago.
29. Stone W.S., Seidman L.J. Towards a model of memory enhancement in schizophrenia: glucose administration and hippocampal function. Schizophr. Bull. 2008, 34:93-108.
30. Stone W.S., Faraone S.V., Seidman L.J., Green A.I., Wojcik J.D., Tsuang M.T. Concurrent validation of schizotaxia: a pilot study. Biol. Psychiatry 2001, 50:434-440.
31. Stone W.S., Faraone S.V., Seidman L.J., Olson E.A., Tsuang M.T. Searching for the liability to schizophrenia: concepts and methods underlying genetic high-risk studies of adolescents. J Child. Adolescent Psychopharmacol. 2005, 15:403-417.
32. Stone W.S., Hsi X., Tan L., Zhu S., Li L., Giuliano A.J., Seidman L.J., Tsuang M.T. Neurocognitive and clinical dysfunction in adult Chinese, nonpsychotic relatives of patients with schizophrenia: Findings from the Changsha study and evidence for schizotaxia. Asian J. Psychiatry 2011, 10.1016/j.ajp.2011.11.007.
33. Tsuang M.T., Stone W.S., Faraone S.V. Schizophrenia: a review of genetic studies. Harvard Rev. Psychiatry 1999, 7:185-207.
34. Tsuang M.T., Stone W.S., Seidman L.J., Faraone S.V., Zimmet S., Wojcik J., Kelleher J., Green A.I. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biol. Psychiatry 1999, 41:1412-1418.
35. Tsuang M.T., Stone W.S., Faraone S.V. Towards reformulating the diagnosis of schizophrenia. Am. J. Psychiatry 2000, 147:1041-1050.
36. Tsuang M.T., Stone W.S., Tarbox S.I., Faraone S.V. Treatment of nonpsychotic relatives of patients with schizophrenia: six case studies. Am. J. Med. Genet. (Neuropsychiatric Gen.) 2002, 114:943-948.
37. Weissman M.M., Bothwell S. Assessment of social adjustment by patient self-report. Arch. Gen. Psychiatry 1976, 33:1111-1115.
38. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 2005, 8:457-472.